SRX246
Irritability/Aggression in Huntington's Disease
Key Facts
About Azevan Pharmaceuticals
Azevan Pharmaceuticals is a private, clinical-stage company pioneering a novel approach to treating CNS disorders by selectively targeting the vasopressin 1a receptor (V1aR). Its lead asset, SRX246, has completed Phase 2 trials in Huntington's disease-related aggression and Intermittent Explosive Disorder, showing clinical benefit and excellent tolerability, and is poised to enter a Phase 2 trial in Fragile X Syndrome. The company's strategy targets high-unmet-need, often rare, neuropsychiatric and neurodevelopmental indications as a pathway to potentially larger markets in TBI and neurodegenerative diseases. Azevan's work is supported by significant non-dilutive funding from U.S. government agencies.
View full company profileAbout Azevan Pharmaceuticals
Azevan Pharmaceuticals is a private, clinical-stage company pioneering a novel approach to treating CNS disorders by selectively targeting the vasopressin 1a receptor (V1aR). Its lead asset, SRX246, has completed Phase 2 trials in Huntington's disease-related aggression and Intermittent Explosive Disorder, showing clinical benefit and excellent tolerability, and is poised to enter a Phase 2 trial in Fragile X Syndrome. The company's strategy targets high-unmet-need, often rare, neuropsychiatric and neurodevelopmental indications as a pathway to potentially larger markets in TBI and neurodegenerative diseases. Azevan's work is supported by significant non-dilutive funding from U.S. government agencies.
View full company profileAbout Azevan Pharmaceuticals
Azevan Pharmaceuticals is a private, clinical-stage company pioneering a novel approach to treating CNS disorders by selectively targeting the vasopressin 1a receptor (V1aR). Its lead asset, SRX246, has completed Phase 2 trials in Huntington's disease-related aggression and Intermittent Explosive Disorder, showing clinical benefit and excellent tolerability, and is poised to enter a Phase 2 trial in Fragile X Syndrome. The company's strategy targets high-unmet-need, often rare, neuropsychiatric and neurodevelopmental indications as a pathway to potentially larger markets in TBI and neurodegenerative diseases. Azevan's work is supported by significant non-dilutive funding from U.S. government agencies.
View full company profileAbout Azevan Pharmaceuticals
Azevan Pharmaceuticals is a private, clinical-stage company pioneering a novel approach to treating CNS disorders by selectively targeting the vasopressin 1a receptor (V1aR). Its lead asset, SRX246, has completed Phase 2 trials in Huntington's disease-related aggression and Intermittent Explosive Disorder, showing clinical benefit and excellent tolerability, and is poised to enter a Phase 2 trial in Fragile X Syndrome. The company's strategy targets high-unmet-need, often rare, neuropsychiatric and neurodevelopmental indications as a pathway to potentially larger markets in TBI and neurodegenerative diseases. Azevan's work is supported by significant non-dilutive funding from U.S. government agencies.
View full company profile